Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Science 37, Inc.

< Previous 1 2 Next >
Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
From Science 37, Inc.
Via GlobeNewswire
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
From Science 37, Inc.
Via GlobeNewswire
Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
From Science 37, Inc.
Via GlobeNewswire
Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
From Science 37, Inc.
Via GlobeNewswire
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
From Science 37, Inc.
Via GlobeNewswire
Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials
From Science 37, Inc.
Via GlobeNewswire
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
From Science 37, Inc.
Via GlobeNewswire
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
From Science 37, Inc.
Via GlobeNewswire
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
From Science 37, Inc.
Via GlobeNewswire
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
From Science 37, Inc.
Via GlobeNewswire
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
From Science 37, Inc.
Via GlobeNewswire
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Receives Top Honors in Everest PEAK Matrix®
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Reports Third Quarter 2023 Financial Results
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
Science 37 Reports Second Quarter 2023 Financial Results
From Science 37, Inc.
Via GlobeNewswire
Tickers SNCE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.